Treatment of thrombotic microangiopathies with plasma exchange.
Thrombotic microangiopathy (TMA) is a syndrome characterized by thrombocytopenia, microangiopathic hemolytic anemia, neurologic abnormalities, fever and renal dysfunction. This retrospective analysis sought to determine the clinical characteristics and outcome of patients with TMA treated with plasma exchange at the Department of Dialysis, University Hospital Zagreb. From 1982 to July 2005, 17 patients (10 male and 7 female, age ranging from 18 to 74 years) have been diagnosed with TMA. The most common presenting symptom was purpura in 76.5%, followed by neurologic disturbance in 70.5%, renal function abnormality in 41.1%, and fever in 29.4% of patients. Patients were treated with a daily plasma exchange, which was continued until the normalization of platelet count with minimal hemolysis. Plasma exchange treatment was first tapered and later discontinued with careful monitoring of laboratory parameters. Of the 17 patients, 13 achieved complete remission after 5-32 sessions, two had partial response, and two had no response and died of progressive disease. Four patients developed chronic relapsing TMA, and three of them progressed to end-stage renal disease. Survival at 1 year in our series exceeds 88%, but decreased with duration of follow-up. Overall, with the median follow up of 5 years, 6 patients died from consequences of TMA (35.3%); three with chronic TMA, and 2 in the acute phase of progressive disease. A 74-year old male who developed TMA after prostate cancer died from disseminated malignant disease. Our results demonstrate a high incidence of renal function abnormalities in patients with TMA at presentation, but also during long term follow-up. Development of end-stage renal disease was associated with poor prognosis. Further studies, long term follow-up and establishment of international registries are needed to clarify many dilemmas associated with the diagnosis, treatment and outcomes of patients with TMA.
Basic-Jukic
Nikolina
N
Department of Dialysis, University Hospital Centre Zagreb, Zagreb, Croatia. nina_basic@net.hr
Kes
Petar
P
Bubic-Filipi
Ljubica
L
Brunetta
Bruna
B
D000230:Adenocarcinoma / Q000150:complications; D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000707:Anaphylaxis / Q000209:etiology; D000743:Anemia, Hemolytic / Q000188:drug therapy / Q000628:therapy*; D002408:Catheters, Indwelling / Q000009:adverse effects; D003131:Combined Modality Therapy; D003221:Confusion / Q000209:etiology; D018450:Disease Progression; D004927:Escherichia coli Infections / Q000150:complications; D005260:Female; D005500:Follow-Up Studies; D006463:Hemolytic-Uremic Syndrome / Q000188:drug therapy / Q000628:therapy*; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D007674:Kidney Diseases / Q000209:etiology; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D010949:Plasma; D010951:Plasma Exchange / Q000009:adverse effects; D011183:Postoperative Complications / Q000628:therapy; D011471:Prostatic Neoplasms / Q000150:complications; D011697:Purpura, Thrombotic Thrombocytopenic / Q000188:drug therapy / Q000628:therapy*; D012189:Retrospective Studies; D013577:Syndrome; D013927:Thrombosis / Q000209:etiology
D000305:Adrenal Cortex Hormones